MetaCap

Annexon (ANNX) vs Olema Oncology (OLMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Annexon (ANNX) has outperformed Olema Oncology (OLMA) over the past year, losing 27.4% versus a loss of 69.7%. Over five years, OLMA leads with a -66.4% price change compared with -77.4% for ANNX. Olema Oncology is the larger company by market cap ($615.0 million vs $591.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANNX-27.40%OLMA-69.70%
+70%-5%-79%
Nov 21, 20251 yearNov 20, 2026
ANNX-78.09%OLMA-69.16%
+52%-23%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANNX versus OLMA key metrics
MetricANNXOLMA
Share price$3.10$7.02
Market cap$591.37M$615.00M
1-day change-9.09%-1.82%
YTD return-38.25%-71.92%
1-year return-27.40%-69.70%
5-year return-77.37%-66.36%
EPS (TTM)$-1.01$-2.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-206.69M$-162.45M
52-week high$7.18$36.26
52-week low$3.07$6.24
Distance from 52-week high-56.82%-80.64%
Analyst consensusbuystrong_buy
Avg. price target upside+448.39%+405.70%
Average volume3.36M1.27M
Shares outstanding190.76M87.61M
Employees97131
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANNX has outperformed OLMA by 42.3 percentage points over the past year.

About Annexon

ANNX stock →

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 97 employees

About Olema Oncology

OLMA stock →

Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees

ANNX vs OLMA FAQ

Which is bigger, Annexon or Olema Oncology?

Olema Oncology (OLMA) is larger, with a market capitalization of $615.00M compared with $591.37M for Annexon (ANNX).

Which stock has performed better over the past year, ANNX or OLMA?

ANNX returned -27.40% over the past 12 months, compared with -69.70% for OLMA (price return, excluding dividends). Past performance does not predict future results.

Are Annexon and Olema Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons